| 2025-11-18 |
详情>>
内部人交易：
Bar-Shalev Amos股份减少168.00股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.01美元,归母净利润-110万美元,同比去年增长69.12%
|
| 2025-11-13 |
财报披露：
美东时间 2025-11-13 盘前发布财报
|
| 2025-08-14 |
详情>>
股本变动：
变动后总股本7973.21万股
变动原因 ▼▲
- 原因：
- From March 31, 2025 to June 30, 2025
Issuance of common stock under the Sales Agreement, net
Exercise of warrants and options
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.04美元,归母净利润-345.5万美元,同比去年增长49.18%
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益-0.05美元,归母净利润-361.9万美元,同比去年增长21.24%
|
| 2025-04-30 |
股东大会：
将于2025-06-26召开股东大会
会议内容 ▼▲
- 1.To elect or re-elect eight members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected;
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice;
3.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2025-04-30 |
股东大会：
将于2025-06-26召开股东大会
会议内容 ▼▲
- 1.To elect or re-elect eight members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected;
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice;
3.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2025-03-17 |
详情>>
业绩披露：
2022年年报每股收益-0.31美元,归母净利润-1492.7万美元,同比去年增长45.88%
|
| 2025-03-17 |
详情>>
业绩披露：
2024年年报每股收益0.04美元,归母净利润293.20万美元,同比去年增长-64.73%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.05美元,归母净利润-356.2万美元,同比去年增长-124.81%
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.09美元,归母净利润-679.8万美元,同比去年增长-141.94%
|
| 2024-08-14 |
详情>>
业绩披露：
2023年中报每股收益0.26美元,归母净利润1620.80万美元,同比去年增长312.70%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.06美元,归母净利润-459.5万美元,同比去年增长-46.76%
|
| 2024-04-29 |
股东大会：
将于2024-06-27召开股东大会
会议内容 ▼▲
- 1.To elect or re-elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected;
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice;
3.To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan;
4.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
5.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2024-04-29 |
股东大会：
将于2024-06-27召开股东大会
会议内容 ▼▲
- 1.To elect or re-elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected;
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice;
3.To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 12,475,171 shares to 17,475,171 shares and to amend certain other terms of said plan;
4.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
5.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2024-03-14 |
详情>>
业绩披露：
2023年年报每股收益0.12美元,归母净利润831.20万美元,同比去年增长155.68%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.22美元,归母净利润1435.60万美元,同比去年增长228.33%
|
| 2023-05-18 |
股东大会：
将于2023-06-28召开股东大会
会议内容 ▼▲
- 1.To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice.
3.To approve, on a non-binding advisory basis, on the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers.
4.To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan;
5.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 144,000,000 to 185,000,000;
6.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
7.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2023-05-18 |
股东大会：
将于2023-06-28召开股东大会
会议内容 ▼▲
- 1.To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice.
3.To approve, on a non-binding advisory basis, on the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers.
4.To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan;
5.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 144,000,000 to 185,000,000;
6.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
7.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2022-04-29 |
股东大会：
将于2022-06-30召开股东大会
会议内容 ▼▲
- 1.To elect six members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice.
3.To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 5,725,171 shares to 8,475,171 shares and to amend certain other terms of said plan;
4.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 120,000,000 to 144,000,000;
5.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
6.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2021-09-30 |
股东大会：
将于2021-11-24召开股东大会
会议内容 ▼▲
- 1.Approve, in accordance with Section 713(a) of the NYSE American Company Guide, the potential issuance of shares representing in excess of 19.99% of our pre-transaction total shares of common stock outstanding that may result from the conversion of, or the satisfaction of make-whole payments on, the 7.50% Senior Secured Convertible Notes Due 2024 we issued on August 25, 2021.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-04 |
股东大会：
将于2021-07-07召开股东大会
会议内容 ▼▲
- 1.To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice.
3.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
4.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2021-04-29 |
复牌提示：
2021-04-28 13:29:03 停牌，复牌日期 2021-04-28 13:34:03
|
| 2020-04-15 |
股东大会：
将于2020-06-07召开股东大会
会议内容 ▼▲
- 1.To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2.To approve,on a non-binding advisory basis,the compensation of the Company’s named executive officers as disclosed in the proxy statement that accompanies this notice.
3.To approve, on a non-binding advisory basis, on the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers.
4.In order to continue to recruit and retain talented employees, to adopt amendments to the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan to increase the number of shares of common stock available under the plan from 2,384,165 shares to 5,725,171 shares and to amend certain other terms of said plan as described in the proxy statement that accompanies this notice.
5.To ratify the appointment of Kesselman & Kesselman,Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
6.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2019-12-20 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2019-10-15 |
股东大会：
将于2019-12-09召开股东大会
会议内容 ▼▲
- 1.Approve an amendment to our Certificate of Incorporation, as amended, to (i) effect a reverse stock split at a ratio not less than 1-for-10 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our Board of Directors before the day prior to the special meeting of stockholders without further approval or authorization of our stockholders and (ii) reduce the total number of shares of our common stock that we are authorized to issue from 350 million shares to 120 million shares.
|
| 2019-10-15 |
股东大会：
将于2019-12-09召开股东大会
会议内容 ▼▲
- 1.Approve an amendment to our Certificate of Incorporation, as amended, to (i) effect a reverse stock split at a ratio not less than 1-for-10 and not greater than 1-for-20, with the exact ratio to be set within that range at the discretion of our Board of Directors before the day prior to the special meeting of stockholders without further approval or authorization of our stockholders and (ii) reduce the total number of shares of our common stock that we are authorized to issue from 350 million shares to 120 million shares.
|
| 2019-04-12 |
股东大会：
将于2019-05-30召开股东大会
会议内容 ▼▲
- 1.Consider the election of directors;
2.Approve an advisory vote on executive compensation;
3.Ratify the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
| 2019-04-12 |
股东大会：
将于2019-05-30召开股东大会
会议内容 ▼▲
- 1.Consider the election of directors;
2.Approve an advisory vote on executive compensation;
3.Ratify the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
| 2018-12-19 |
股东大会：
将于2019-01-10召开股东大会
会议内容 ▼▲
- 1.approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 250,000,000 to 350,000,000.
|
| 2018-03-06 |
股东大会：
将于2018-04-15召开股东大会
会议内容 ▼▲
- 1. To elect five members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement that accompanies this notice.
3. To adopt amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan to increase the number of shares of common stock available under the plan from 13,841,655 shares to 23,841,655 shares and to amend certain other terms of said plan as described in the proxy statement that accompanies this notice.
4. To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 250,000,000 to 350,000,000.
5. To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
6. To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2017-08-25 |
股东大会：
将于2017-10-19召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Section 713(a) of the NYSE American Company Guide, the potential issuance of shares representing in excess of 19.9% of our pre-transaction total shares of common stock outstanding that may result from the conversion of, or payment of accrued interest or make-whole payments on, the 7.50% Senior Secured Convertible Notes Due 2021 we issued on July 25, 2017 and the 4.50% Senior Convertible Notes Due 2022 we issued on July 25, 2017.
2.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 250,000,000 to 350,000,000.
|
| 2017-08-25 |
股东大会：
将于2017-10-19召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Section 713(a) of the NYSE American Company Guide, the potential issuance of shares representing in excess of 19.9% of our pre-transaction total shares of common stock outstanding that may result from the conversion of, or payment of accrued interest or make-whole payments on, the 7.50% Senior Secured Convertible Notes Due 2021 we issued on July 25, 2017 and the 4.50% Senior Convertible Notes Due 2022 we issued on July 25, 2017.
2.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 250,000,000 to 350,000,000.
|
| 2017-03-16 |
股东大会：
将于2017-04-12召开股东大会
会议内容 ▼▲
- 1.To elect six members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement that accompanies this notice.
3.To approve, in accordance with Section 713(a) of the NYSE MKT Company Guide, the potential issuance of shares representing in excess of 19.9% of our pre-transaction total shares of common stock outstanding that may result from the conversion of, or payment of accrued interest on, our outstanding 7.50% Senior Secured Convertible Notes Due 2021.
4.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 250,000,000 to 300,000,000.
5.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
6.To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2016-07-01 |
股东大会：
将于2016-08-07召开股东大会
会议内容 ▼▲
- 1. To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement that accompanies this notice.
3. To approve an amendment to our Certificate of Incorporation to increase the number of shares of our common stock, par value $0.001 per share, authorized for issuance from 150,000,000 to 250,000,000.
4. To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
5. To transact such other business that is properly presented at the meeting or any adjournment.
|
| 2015-10-01 |
股东大会：
将于2015-11-08召开股东大会
会议内容 ▼▲
- 1.To elect seven members to the Board of Directors to serve for the ensuing year or until their respective successors have been duly elected.
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement that accompanies this notice.
3.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountant (lsr.), a member of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
4.To transact such other business that is properly presented at the meeting or any adjournment.
|